Immediate Impact
57 standout
Citing Papers
An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013–2023)
2024 Standout
Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders
2024 Standout
Works of John Landry being referenced
Prognostic factors for changes in the timed 4-stair climb in patients with Duchenne muscular dystrophy, and implications for measuring drug efficacy: A multi-institutional collaboration
2020
Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta‐analysis of disease progression rates in recent multicenter clinical trials
2019
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| John Landry | 173 | 89 | 106 | 94 | 24 | 444 | |
| Madhubhashinee Dayabandara | 228 | 75 | 53 | 112 | 16 | 429 | |
| Nikhil Nihalani | 167 | 100 | 35 | 53 | 24 | 510 | |
| Joanna Le Noury | 204 | 85 | 38 | 77 | 20 | 485 | |
| Sung-Won Jung | 116 | 117 | 33 | 50 | 19 | 474 | |
| Luciano K. Jornada | 190 | 50 | 77 | 44 | 25 | 480 | |
| Celine Teo | 220 | 31 | 96 | 110 | 33 | 437 | |
| Victor Vieweg | 282 | 30 | 71 | 68 | 19 | 502 | |
| Per Vendsborg | 246 | 39 | 53 | 35 | 33 | 499 | |
| Om Prakash | 206 | 50 | 31 | 37 | 41 | 462 | |
| Seren Roberts | 108 | 39 | 47 | 46 | 16 | 417 |
All Works
Loading papers...